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A 68-year old woman undergoing a routine surveillance endoscopy—part of her follow-up for 
a Barrett’s oesophagus—was found to have a solitary, 4 mm, black lesion in the gastric body 
(Figure A). Biopsies were taken which showed mucosa typical of the gastric body with heavily 
pigmented cells within the lamina propria infiltrating around the crypts without destroying them 
(Figure B). Immunohistochemical examination of biopsied tissue section showed positive 
staining for melanoma associated antigens using antibodies including Melan-A, HMB-45, 
MITF, and SOX-10. Her medical history included the enucleation of her left eye 13 years earlier 
to remove a primary uveal melanoma; she had been discharged from routine follow-up. We 
then decided to carry out another gastroscopy to take deeper gastric biopsies. These showed 
infiltration of the muscularis mucosae by melanocytes with mild atypia. A full-body CT scan 
showed multiple lesions in her liver which on subsequent MRI were confirmed to be melanin-
laden metastases (Figure C). Gene mutation panel testing on the gastric biopsy specimens and 
on the ocular specimens taken at the time of the eye operation 13 years earlier, showed the same 
oncogenic mutation: Gln209Leu in GNA11. Tests for the common cutaneous melanoma 
mutations in BRAF, NRAS, and KIT genes were negative. The patient was enrolled in a clinical 
trial testing a combination of selumetinib and paclitaxel chemotherapy for metastatic uveal 
melanoma. 
Uveal melanoma is a rare cancer representing less than 5% of all melanomas; it has a nearly 
50-fold lower incidence rate compared with that of cutaneous melanomas. It is an aggressive 
disease predominantly spreading to the liver in up to 50% of patients. Median survival with 
liver metastases is under 6 months. Currently, there are no effective non-surgical treatments for 
metastatic uveal melanoma. Surveillance and monitoring of the liver—after treatment of the 
primary lesion—is recommended so that patients can receive early locoregional treatments. The 
length of time patients should be followed-up is not established in current clinical guidelines.  
Uveal melanoma is associated with an almost linear continuation of recurrence over time and 
beyond 10 years without a plateau in risk of recurrence over time. Thus, late recurrences are 
not uncommon: 5- and 10-year cumulative metastasis rate is 25% and 34%, respectively. 
Cutaneous and uveal melanomas are biologically distinct. Uveal melanomas lack the typical 
cutaneous melanoma-associated mutations in the BRAF, NRAS and NF1 genes, but have 
somatic mutations in the GNA11 and QNAQ genes in around 90% of cases—in cutaneous 
melanomas mutations in these genes are found in less than 10% of cases. Mutations in these 
genes activate the MAP kinase oncogenic pathway, providing a rationale for using MEK1/2 
inhibitors, selumetinib for example, as agents in clinical trials results—although to date the 
results have been disappointing.  Functionally activating mutations in GNAQ and GNA11, as 
well as in CYSLTR2 and PLCB4, leads to the subsequent activation of pathways—which include 
the PI3kinase and Yap/Hippo pathways—downstream beyond the MAP kinase pathway. These 
may offer potential novel therapeutic targets. Genetic profiling of primary uveal melanomas 
has some prognostic value. For example, inactivating mutations in the BAP1 gene—found in 
approximately 50% of cases—are highly likely to metastasise, whereas mutations in the SF3B1 
and EIF1AX genes, occurring in approximately 19% and 24% of uveal melanoma cases 
respectively, are less likely to metastasise.  
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 Figure: Surprise black finding at routine endoscopy for Barrett’s oesophagus 
(A) Solitary, 4mm, black lesion on the greater curvature of the mid-gastric body seen at 
endoscopy. (B) Typical gastric body mucosa shows heavily pigmented cells within the lamina 
propria infiltrating around the crypts (haematoxylin and eosin stain). Original magnification x 
5. (C) Contrast-enhanced MRI shows multiple T1-hyperintense lesions in the liver—the largest 
measured up to 2 cm. The lesions were hypointense on T2-weighted and diffusion-weighted 
imaging. 
 
